Speciality Medicines SME IPO GMP History
Speciality Medicines SME IPO has been listed on March 30, 2026 at a listing price of ₹124, against the issue price of ₹124 — a gain of ₹0 (+0%). The GMP peaked at ₹0 on 29 March 2026 and reached a low of ₹0 on 29 March 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Speciality Medicines SME IPO raised ₹29 Cr. through its IPO at a price band of ₹117 to ₹124 per share, with a lot size of 1000 shares. The IPO was open for subscription from 20 Mar 2026 to 24 Mar 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 3 Sep, 2:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 29 Mar 2026 | ₹ 0 | — | -- | — | — |
| 28 Mar 2026 | ₹ 0 | — | -- | — | — |
| 25 Mar 2026 | ₹ 0 | — | -- | — | — |
| 24 Mar 2026 | ₹ 0 | — | -- | — | — |
| 23 Mar 2026 | ₹ 0 | — | -- | — | — |
| 21 Mar 2026 | ₹ 0 | — | -- | — | — |
| 20 Mar 2026 | ₹ 0 | — | -- | — | — |
| 19 Mar 2026 | ₹ 0 | — | -- | — | — |
| 18 Mar 2026 | ₹ 0 | — | -- | — | — |
Speciality Medicines SME IPO dates
Key dates from opening to listing. Today is 3 October.
- Open 20 Mar 2026
- Close 24 Mar 2026
- Allotment 25 Mar 2026
- Refund/credit 27 Mar 2026
- Listing 30 Mar 2026
Speciality Medicines SME IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹124 |
|---|---|
| Listing gain / loss | +₹0 per share |
| Listing date | 30 Mar, 2026 |
| Actual listing price | ₹124 (+0%) |
Is Speciality Medicines SME IPO GMP reliable?
Grey market premium for Speciality Medicines SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Speciality Medicines SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Speciality Medicines SME IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Speciality Medicines SME IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Speciality Medicines SME IPO
Speciality Medicines Limited was established with the objective of catering to the growing demand for niche and high-value pharmaceutical products in India. Over the years, the company has built its presence in the healthcare sector by focusing on specialised therapeutic segments such as critical care, oncology, and chronic disease management. Promoted by experienced professionals from the pharmaceutical industry, the company has developed strong relationships with hospitals, healthcare institutions, and distributors across key regions.
The company’s business model revolves around sourcing, marketing, and distribution of speciality drugs, along with a focus on quality and regulatory compliance. It offers a diverse portfolio of branded and generic medicines, targeting both domestic and selected international markets. By leveraging an asset-light approach and an efficient supply chain network, Speciality Medicines Limited aims to scale its operations while maintaining consistent product availability and expanding its reach in the healthcare ecosystem.
Frequently asked
What is the GMP of Speciality Medicines SME IPO?
The current Grey Market Premium (GMP) of Speciality Medicines SME IPO is not yet started or active in the market.
What is the Kostak Price of Speciality Medicines SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Speciality Medicines SME IPO is not available.
What is the Subject to Sauda Price of Speciality Medicines SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Speciality Medicines SME IPO?
Speciality Medicines SME IPO listed on March 30, 2026 at ₹124, against the issue price of ₹124 — a gain of +0%.
How did the GMP of Speciality Medicines SME IPO trend before listing?
The GMP of Speciality Medicines SME IPO was stable in its final days before listing. The GMP peaked at ₹0 on 29 March 2026. View the day-wise table above for the complete GMP history.
Explore Speciality Medicines SME IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
